
INFORMATION ONLY**Intravenous Immunoglobulin (IVIg) Brand Switching Guidance and Resources from
The National Advisory Committee on Blood and Blood Products (NAC)****Customer Letter # 2021-17**

2021-03-03

Dear Colleagues:

As previously communicated in Customer Letter [#2020-50](#), Canada is facing challenges related to immunoglobulin (Ig) products and there have been important changes to the national intravenous immunoglobulin (IVIg) share splits. Hospitals have been asked to align with the projected share splits by April 1, 2021.

To help support hospitals with the changes required, the National Advisory Committee on Blood and Blood Products (NAC) is sharing the following five resources:


1. Clinical Practice Considerations: Intravenous Immunoglobulin (IVIg) Brand Switching (see attached)
2. Fact Sheet: Canadian Immunoglobulin (Ig) Supply and Intravenous Immunoglobulin (IVIg) Brand Switching
3. Template Communication to the Prescribing Physician: IVIg Brand Switching for Chronic IVIg Infusion Patients
4. Template Communication to the Patient: Notification of IVIg Brand Switch
5. Transfusion Safety: Notice of IVIg Brand Switch at Product Issue (example from Alberta Precision Laboratories)

To access the above resources, please consult the [NAC website](#). Resources (#3-5) may be customized for hospital or regional use.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the "Hospitals Services" section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,



Sylvain Grenier
Director, Plasma Protein and Related Products Formulary Program